EP2584919A1 - Prebiotic effect of galactofructose - Google Patents

Prebiotic effect of galactofructose

Info

Publication number
EP2584919A1
EP2584919A1 EP11725943.2A EP11725943A EP2584919A1 EP 2584919 A1 EP2584919 A1 EP 2584919A1 EP 11725943 A EP11725943 A EP 11725943A EP 2584919 A1 EP2584919 A1 EP 2584919A1
Authority
EP
European Patent Office
Prior art keywords
galactofructose
days
food composition
prebiotic effect
daily doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11725943.2A
Other languages
German (de)
French (fr)
Inventor
Pascal Ronfard
Guillaume Baxter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GROUPE SOLACTIS
Original Assignee
Solvay SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay SA filed Critical Solvay SA
Publication of EP2584919A1 publication Critical patent/EP2584919A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to the prebiotic effect of oligosaccharides on the intestinal flora of mammals.
  • a prebiotic is a non-digestible food compound that can be broken down by the microorganisms of the intestinal flora. This breakdown gives rise to an effect on the intestinal flora of the mammal, beneficial to the health thereof since it leads to development of certain bacteria of the flora.
  • bifidobacteria are known for having an important role, for example in the immune system of the hosts. Their selective development by virtue of prebiotic compounds
  • the prebiotic effect of a non-living compound refers to the change, both in composition and in activity, of the intestinal flora of the host due to the ingestion of this compound, when this change has a beneficial effect on the well-being and/or the health of the host (see: Gibson and Roberfroid, J. Nutr, 125, 1401, 1995).
  • probiotic refers, on the other hand, to a food supplement comprising living microorganisms, when these microorganisms have a beneficial effect on the host by improving the balance of its intestinal flora (see: Fuller, J. of Applied Bacteriology, 66 (5), 365-378, 1989).
  • oligosaccharides The prebiotic effect of certains oligosaccharides is known. Described in FR2844453 is the prebiotic effect of non-digestible oligosaccharides comprising chain formations of identical or different monosaccharides, the degree of polymerization of which varies between 2 and 10. These oligosaccharides, via their prebiotic effect, may contribute to the prevention of type II diabetes.
  • oligosaccharides in FR2844453 are intended for patients predisposed to type II diabetes. Taking oligosaccharides is similar to taking medication.
  • the invention aims to improve the well-being of healthy mammals, via acting on their intestinal flora.
  • the invention relates to galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
  • Galactofructose also called lactulose, is a disaccharide formed from the combination of two monosaccharide molecules, fructose and galactose. Its chemical formula is (4-0-p-D-Galactopyranosyl-P-D-fructofuranose). It is an isomerization product of lactose, which both have the same empirical formula
  • galactofructose when it is absorbed in small amounts according to the invention in food compositions, improves the well- being of mammals.
  • the invention also has the advantage of not interfering with the taste and the appearance (for example colour) of the food compositions.
  • the galactofructose according to the invention is incorporated into a food composition.
  • the expression "food composition” is understood to mean a composition intended for feeding mammals.
  • the mammals are preferably human beings, although the invention can also be used for improving the well-being of various mammalian animals, such as domestic animals.
  • the food composition is advantageously a composition absorbed regularly, preferably at least once a week, more preferably several times a week, and particularly preferably daily.
  • Food compositions for human beings comprising at least one foodstuff such as bread, butter, milk, fermented dairy products, cereals, biscuits, beverages and fruit juices are advantageous.
  • the food compositions are intended for feeding children.
  • a food composition comprising powdered milk intended for infant feed is one example of a food composition for which the invention is particularly suitable.
  • the galactofructose is absorbed in daily amounts, averaged over 30 days, of between 0.05 and 0.5 gram. This means that the daily doses may vary but that the total dose absorbed over one month divided by 30 is between 0.05 and 0.5 g.
  • the amounts are averaged over 7 days, which means that the total dose absorbed over seven days divided by 7 is between 0.05 and 0.5 g.
  • the daily doses of galactofructose, averaged over 30 days are between 0.1 and 0.5 g, more advantageously between 0.2 and 0.5 and more advantageously still between 0.2 and 0.4 g. It is recommended that the daily dose absorbed, not averaged, does not exceed 5 g, preferably does not exceed 2.5 g, more preferably does not exceed
  • the daily doses of galactofructose are between 0.1 and 0.5 g, over at least 7 days, preferably at least 14 days, more preferably at least 30 days.
  • galactofructose is absorbed regularly every day and the doses are no longer averages, but daily estimated values.
  • the prebiotic effect according to the invention is demonstrated in concrete terms by an increase in the population of bifidobacteria in the intestinal flora of the host mammal.
  • This increase is at least 10%, generally at least 25%, often at least 50%.
  • the population is at least doubled.
  • the population of Bifidobacterium spp bifidobacteria, expressed in log 10 is increased by 0.5 at least, which corresponds to a multiplication of the population by a factor of around 3 at least.
  • Bifidobacterium spp bifidobacteria protect the gut against colonization by pathogenic bacteria.
  • This protection results, on the one hand, from the competition at the surface of the cells, from the competition for essential nutrients, from the production of antimicrobial agents and from the production of compounds comprising short-chain fatty acids, which decrease the pH of the faeces and inhibit the development of pathogenic bacteria.
  • Bifidobacterium spp bifidobacteria are also associated with a strengthening of the immune system, especially in children, and with a preventive action against cancer, via a reduction in the activity of enzymes that convert procarcinogenic substances into carcinogenic substances (see von Wright et al., Eur J.
  • the increase in the population of bifidobacteria does not require any probiotic in the food composition. It is even recommended that the composition be substantially free thereof.
  • the expression “substantially free of probiotics”, is understood to mean that the food composition alone, in the absence of galactofructose, gives rise to an increase in the population of
  • the invention is preferably aimed at mammals in good health, exhibiting no signs of disease. It makes it possible to improve their well-being. Under certain circumstances, it also makes it possible to protect their good health, in a preventative manner.
  • the invention also relates to a food composition as is, comprising galactofructose for its prebiotic effect on the intestinal flora of mammals, when the food composition is absorbed in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
  • the food composition according to the invention is advantageously a regularly absorbed composition, and preferably contains a foodstuff intended for children, such as powdered milk for infant feed.
  • this is also substantially free of probiotics.
  • the invention also relates to a prepackaged dose of the composition as herein described, comprising from 0.1 to 0.5 gram of galactofructose. It is recommended to absorb such a dose daily.
  • the invention finally relates to a process for manufacturing a composition according to the invention, according to which a galactofructose powder, having a water content of less than 5% by weight and an average particle size D50 of less than 500 ⁇ , is mixed with a foodstuff.
  • the powder may be manufactured according to the process described in FR2898516.
  • the process according to the invention is particularly advantageous when the foodstuff is itself in powder form, as is the case of milk powders for feeding children, for example.
  • the bifidobacterium spp population of the faeces before the test, measured by the FISH (Fluorescence In Situ Hybridization) technique was around 8.5 logl O cells/g faeces on average. At the end of the test (30 days), this population increased to around 9 log 10 in the group absorbing galactofructose according to the invention. No significant variation (taking into account natural variations in measurement) was observed in the placebo group. 30 days after the end of the ingestion, the bifidobacterium population of the galactofructose group returned to a value close to 8.75 on average. Furthermore, it was verified that the total population of anaerobic bacteria varied little during and after the test, both in the galactofructose group and in the placebo group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

Galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.

Description

PREBIOTIC EFFECT OF GALACTOFRUCTOSE
The invention relates to the prebiotic effect of oligosaccharides on the intestinal flora of mammals.
A prebiotic is a non-digestible food compound that can be broken down by the microorganisms of the intestinal flora. This breakdown gives rise to an effect on the intestinal flora of the mammal, beneficial to the health thereof since it leads to development of certain bacteria of the flora. Among these, bifidobacteria are known for having an important role, for example in the immune system of the hosts. Their selective development by virtue of prebiotic compounds
(bifidogenic prebiotic effect) is therefore beneficial to the well-being of the host mammal. Therefore, the prebiotic effect of a non-living compound refers to the change, both in composition and in activity, of the intestinal flora of the host due to the ingestion of this compound, when this change has a beneficial effect on the well-being and/or the health of the host (see: Gibson and Roberfroid, J. Nutr, 125, 1401, 1995).
It should be noted that probiotic refers, on the other hand, to a food supplement comprising living microorganisms, when these microorganisms have a beneficial effect on the host by improving the balance of its intestinal flora (see: Fuller, J. of Applied Bacteriology, 66 (5), 365-378, 1989).
The prebiotic effect of certains oligosaccharides is known. Described in FR2844453 is the prebiotic effect of non-digestible oligosaccharides comprising chain formations of identical or different monosaccharides, the degree of polymerization of which varies between 2 and 10. These oligosaccharides, via their prebiotic effect, may contribute to the prevention of type II diabetes.
However, the prebiotic use of oligosaccharides in FR2844453 is intended for patients predisposed to type II diabetes. Taking oligosaccharides is similar to taking medication.
The invention aims to improve the well-being of healthy mammals, via acting on their intestinal flora.
Consequently, the invention relates to galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
Galactofructose, also called lactulose, is a disaccharide formed from the combination of two monosaccharide molecules, fructose and galactose. Its chemical formula is (4-0-p-D-Galactopyranosyl-P-D-fructofuranose). It is an isomerization product of lactose, which both have the same empirical formula
(Ci2H220) i) and molecular weight (342.3).
It has been observed that galactofructose, when it is absorbed in small amounts according to the invention in food compositions, improves the well- being of mammals. The invention also has the advantage of not interfering with the taste and the appearance (for example colour) of the food compositions.
The galactofructose according to the invention is incorporated into a food composition. The expression "food composition" is understood to mean a composition intended for feeding mammals. The mammals are preferably human beings, although the invention can also be used for improving the well-being of various mammalian animals, such as domestic animals. The food composition is advantageously a composition absorbed regularly, preferably at least once a week, more preferably several times a week, and particularly preferably daily.
Food compositions for human beings comprising at least one foodstuff such as bread, butter, milk, fermented dairy products, cereals, biscuits, beverages and fruit juices are advantageous.
In one particularly preferred embodiment of the invention, the food compositions are intended for feeding children. A food composition comprising powdered milk intended for infant feed is one example of a food composition for which the invention is particularly suitable.
According to the invention, the galactofructose is absorbed in daily amounts, averaged over 30 days, of between 0.05 and 0.5 gram. This means that the daily doses may vary but that the total dose absorbed over one month divided by 30 is between 0.05 and 0.5 g.
In a first advantageous embodiment, the amounts are averaged over 7 days, which means that the total dose absorbed over seven days divided by 7 is between 0.05 and 0.5 g.
In another advantageous embodiment of the invention, the daily doses of galactofructose, averaged over 30 days, are between 0.1 and 0.5 g, more advantageously between 0.2 and 0.5 and more advantageously still between 0.2 and 0.4 g. It is recommended that the daily dose absorbed, not averaged, does not exceed 5 g, preferably does not exceed 2.5 g, more preferably does not exceed
In one preferred variant, the daily doses of galactofructose are between 0.1 and 0.5 g, over at least 7 days, preferably at least 14 days, more preferably at least 30 days. In this variant, galactofructose is absorbed regularly every day and the doses are no longer averages, but daily estimated values.
The prebiotic effect according to the invention is demonstrated in concrete terms by an increase in the population of bifidobacteria in the intestinal flora of the host mammal. This increase is at least 10%, generally at least 25%, often at least 50%. Preferably, the population is at least doubled. Particularly preferably, the population of Bifidobacterium spp bifidobacteria, expressed in log 10, is increased by 0.5 at least, which corresponds to a multiplication of the population by a factor of around 3 at least. Bifidobacterium spp bifidobacteria protect the gut against colonization by pathogenic bacteria. This protection results, on the one hand, from the competition at the surface of the cells, from the competition for essential nutrients, from the production of antimicrobial agents and from the production of compounds comprising short-chain fatty acids, which decrease the pH of the faeces and inhibit the development of pathogenic bacteria.
Bifidobacterium spp bifidobacteria are also associated with a strengthening of the immune system, especially in children, and with a preventive action against cancer, via a reduction in the activity of enzymes that convert procarcinogenic substances into carcinogenic substances (see von Wright et al., Eur J.
Gastroenterol. Hepatol. November 1999, 11(11), pp. 1195-1198).
Owing to the invention, the increase in the population of bifidobacteria does not require any probiotic in the food composition. It is even recommended that the composition be substantially free thereof. The expression "substantially free of probiotics", is understood to mean that the food composition alone, in the absence of galactofructose, gives rise to an increase in the population of
Bifidobacterium spp of less than 10%, generally of less than 5%.
The invention is preferably aimed at mammals in good health, exhibiting no signs of disease. It makes it possible to improve their well-being. Under certain circumstances, it also makes it possible to protect their good health, in a preventative manner.
The invention also relates to a food composition as is, comprising galactofructose for its prebiotic effect on the intestinal flora of mammals, when the food composition is absorbed in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
In the same way as for the galactofructose according to the invention, the food composition according to the invention is advantageously a regularly absorbed composition, and preferably contains a foodstuff intended for children, such as powdered milk for infant feed.
In one preferred embodiment variant of the food composition according to the invention, this is also substantially free of probiotics.
The invention also relates to a prepackaged dose of the composition as herein described, comprising from 0.1 to 0.5 gram of galactofructose. It is recommended to absorb such a dose daily.
The invention finally relates to a process for manufacturing a composition according to the invention, according to which a galactofructose powder, having a water content of less than 5% by weight and an average particle size D50 of less than 500 μπι, is mixed with a foodstuff. The powder may be manufactured according to the process described in FR2898516.
The process according to the invention is particularly advantageous when the foodstuff is itself in powder form, as is the case of milk powders for feeding children, for example.
The following example serves to illustrate the invention.
Example
20 human volunteers, aged from 18 to 50 years old, having a body mass index of between 20 and 30 were randomly split into two groups of 10, one group absorbing, every day, for 30 days, a 20 cl glass of milk produced from powdered milk to which 0.5 g of Solactis® powder are added, corresponding to 0.3 g of galactofructose, and the other group absorbing a placebo. The volunteers did not display any sign of disease, in particular of intestinal disease. They had never participated in a test relating to prebiotics or probiotics. During the test they did not absorb any probiotic. Yoghurts were avoided. The bifidobacterium spp population of the faeces before the test, measured by the FISH (Fluorescence In Situ Hybridization) technique was around 8.5 logl O cells/g faeces on average. At the end of the test (30 days), this population increased to around 9 log 10 in the group absorbing galactofructose according to the invention. No significant variation (taking into account natural variations in measurement) was observed in the placebo group. 30 days after the end of the ingestion, the bifidobacterium population of the galactofructose group returned to a value close to 8.75 on average. Furthermore, it was verified that the total population of anaerobic bacteria varied little during and after the test, both in the galactofructose group and in the placebo group.

Claims

C L A I M S
1. Galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.05 and 0.5 g.
2. Galactofructose according to Claim 1, in which the daily doses, averaged over 30 days, of galactofructose are between 0.1 and 0.5 g.
3. Galactofructose according to Claim 1 , in which the daily doses, averaged over 30 days, of galactofructose are between 0.2 and 0.4 g.
4. Galactofructose for its prebiotic effect on the intestinal flora of mammals, when it is incorporated into a food composition and when this is absorbed by the mammal in an amount corresponding to daily doses of galactofructose of between 0.05 and 0.5 g over at least 30 days.
5. Food composition comprising at least one foodstuff and
galactofructose for its prebiotic effect on the intestinal flora of mammals, when the food composition is absorbed in an amount corresponding to daily doses, averaged over 30 days, of galactofructose of between 0.05 and 0.5 g.
6. Galactofructose according to one of Claims 1 to 4 or food composition according to the preceding claim, in which the prebiotic effect results in an increase of more than 100% of the population of Bifidobacterium spp.
7. Composition according to either of Claims 5 and 6, substantially free of probiotics.
8. Composition according to one of Claims 5 to 7, comprising less than 25%) by total weight of sugars such as fructose, epilactose, galactose or lactose relative to the amount of galactofructose.
9. Prepackaged dose of the composition according to one of Claims 5 to 8, comprising from 0.1 to 0.5 gram of galactofructose.
10. Process for manufacturing a composition according to one of Claims 5 to 8 or the dose according to Claim 9, according to which a galactofructose powder, having a water content of less than 5% by weight is mixed with a foodstuff.
EP11725943.2A 2010-06-22 2011-06-20 Prebiotic effect of galactofructose Ceased EP2584919A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1054956A FR2961378A1 (en) 2010-06-22 2010-06-22 PREBIOTIC EFFECT OF OLIGOSACCHARIDES
PCT/EP2011/060226 WO2011161053A1 (en) 2010-06-22 2011-06-20 Prebiotic effect of galactofructose

Publications (1)

Publication Number Publication Date
EP2584919A1 true EP2584919A1 (en) 2013-05-01

Family

ID=43259763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11725943.2A Ceased EP2584919A1 (en) 2010-06-22 2011-06-20 Prebiotic effect of galactofructose

Country Status (4)

Country Link
EP (1) EP2584919A1 (en)
JP (1) JP2013530701A (en)
FR (1) FR2961378A1 (en)
WO (1) WO2011161053A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865593A (en) * 1956-03-10 1961-04-19 Tervalon Nv Improvements in or relating to methods of producing bifidus-active food preparations
JP4008974B2 (en) * 1996-12-12 2007-11-14 森永乳業株式会社 Bifidobacterium growth promoting composition and use thereof
FR2844453B1 (en) 2002-09-13 2006-05-19 Agronomique Inst Nat Rech USE OF PRE-BIOTICS FOR PREVENTING THE INSTALLATION OF TYPE II DIABETES
US20040191295A1 (en) * 2003-03-28 2004-09-30 Locniskar Mary Frances Composition and method for viral inhibition
FR2898516B1 (en) 2006-03-17 2008-05-30 Innov Ia Sa PROCESS FOR THE PREPARATION OF A PULVERULENT COMPOSITION AND PRODUCT THEREFORE
CN101460183A (en) * 2006-04-10 2009-06-17 亚历山大·弗拉基米罗维奇·迪科夫斯基 Intestinal adsorbent and prebiotic composition, dosage form, and method for preventing and treating digestive tract disorders
ITMI20071214A1 (en) * 2007-06-15 2008-12-16 S I I T Srl Servizio Internazi COMPOSITIONS BASED ON PREBIOTIC AND IMMUNOGENIC COMPONENTS FOR THE PREVENTION AND TREATMENT OF GASTROENTERIC DISORDERS FROM DISBIOSIS AND / OR ALTERATIONS OF THE NORMAL INTESTINAL FLORA

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Baby Feeding Guide | Nestlé Baby", 19 September 2014 (2014-09-19), XP055189409, Retrieved from the Internet <URL:http://web.archive.org/web/20140919195438/http://www.nestle-baby.ca/en/baby-nutrition/feeding-your-baby/baby-feeding-guide> [retrieved on 20150515] *
ANONYMUS: "BABY FEEDING GUIDE - FROM BIRTH TO PRE-SCHOOL!", 19 September 2014 (2014-09-19), XP055189406, Retrieved from the Internet <URL:http://www.nestle-baby.ca/sites/default/files/files/3_2_3a - Nestlebaby-Feeding-Guide(1).pdf> [retrieved on 20150515] *
R. NAGENDRA ET AL: "Effect of feeding milk formula containing lactulose to infants on faecal bifidobacterial flora", NUTRITION RESEARCH, vol. 15, no. 1, 1 January 1995 (1995-01-01), pages 15 - 24, XP055189305, ISSN: 0271-5317, DOI: 10.1016/0271-5317(95)91649-W *
See also references of WO2011161053A1 *

Also Published As

Publication number Publication date
FR2961378A1 (en) 2011-12-23
WO2011161053A1 (en) 2011-12-29
JP2013530701A (en) 2013-08-01

Similar Documents

Publication Publication Date Title
Patel et al. Emerging prospects of macro-and microalgae as prebiotic
EP1481682B1 (en) Preparation that contains oligosaccharides and probiotics
Aida et al. Mushroom as a potential source of prebiotics: a review
Macfarlane Prebiotics in the gastrointestinal tract
Rehman et al. Influence of fermentable carbohydrates on the intestinal bacteria and enteropathogens in broilers
Nakamura et al. Evaluation of the effects of dietary organic germanium, ge-132, and raffinose supplementation on caecal flora in rats
JP5916288B2 (en) Process for producing innate immunity activator with enhanced innate immunity promoting action and royal jelly-derived innate immunity activator produced by the process
JP7252904B2 (en) Composition for improving intestinal barrier function
JP2823640B2 (en) Intestinal flora improving substance
KR101472190B1 (en) Composition for preventing, treating or improving constipation comprising plant originated tyndalized lactic acid bacteria, Lactobacillus plantarum PMO08 dead cell as an active ingredient
Nguyen et al. Synthesis of oligosaccharide-containing orange juice using glucansucrase
Sharma et al. Pre-and probiotics: Using functional foods in the fight against microbial resistance to antibiotics
WO2011161053A1 (en) Prebiotic effect of galactofructose
WO2024121103A1 (en) Probiotics for treating and/or preventing conditions associated with helicobacter pylory colonization
JPWO2016136624A1 (en) Immunomodulators and uses thereof
Haddadin et al. The effect of royal jelly on growth and short-chain fatty acid production of probiotic bacteria and activity of bacterial procarcinogenic enzymes in rat faeces
US20130316049A1 (en) Galactofructose for its regulating effect on intestinal transit
IT202000015268A1 (en) VEGETABLE FIBER HYDROLYSATE AND ITS USES IN HUMAN AND ANIMAL NUTRITION
JP7854503B2 (en) Composition for promoting oligosaccharide assimilation of Bifidobacterium breve
JP2001002568A (en) Foods or pharmaceuticals intended to prevent or treat menopausal and adulthood indefinite complaint syndrome
JP7141387B2 (en) In vivo phenol compound reducing agent
JP2006265142A (en) Body fat accumulation inhibitor or reducer
KR102133218B1 (en) Composition comprising fat reduction aid andbetaglucan as an effective ingredient for preventing or treating of obesity
JP2006193489A (en) Body fat accumulation inhibitor
Malinowska-Pańczyk 16 Probiotics and

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GROUPE SOLACTIS

17Q First examination report despatched

Effective date: 20150522

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20170519